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Objective: HIV-positive women are known to be at high-risk of human papillomavirus (HPV)
infection and its associated cervical pathology. Here, we describe the prevalence and dis-
tribution of HPV genotypes among HIV-positive and -negative women in South Africa, with
and without cervical intraepithelial neoplasia (CIN).
Methods: We report data on 1,371 HIV-positive women and 8,050 HIV-negative women,
aged 17–65 years, recruited into three sequential studies in Cape Town, South Africa, con-
ducted among women who had no history of cervical cancer screening recruited from the
general population. All women were tested for HIV. Cervical samples were tested for high-
risk HPV DNA (Hybrid Capture 2) with positive samples tested to determine the specific
genotype (Line Blot). CIN status was determined based on colposcopy and biopsy.
Results:The HPV prevalence was higher among HIV-positive women (52.4%) than among
HIV-negative women (20.8%) overall and in all age groups. Younger women, aged 17–
19 years, had the highest HPV prevalence regardless of HIV status. HIV-positive women
were more likely to have CIN 2 or 3 than HIV-negative women. HPV 16, 35, and 58 were
the most common high-risk HPV types with no major differences in the type distribution
by HIV status. HPV 18 was more common in older HIV-positive women (40–65 years) with
no or low grade disease, but less common in younger women (17–29 years) with CIN 2 or
3 compared to HIV-negative counterparts (p<0.03). Infections with multiple high-risk HPV
types were more common in HIV-positive than HIV-negative women, controlling for age
and cervical disease status.
Conclusion: HIV-positive women were more likely to have high-risk HPV than HIV-negative
women; but, among those with HPV, the distribution of HPV types was similar by HIV sta-
tus. Screening strategies incorporating HPV genotyping and vaccination should be effective
in preventing cervical cancer in both HIV-positive and -negative women living in sub-Saharan
Africa.
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INTRODUCTION
Persistent infection with one of the 13 high oncogenic risk human
papillomavirus genotypes (hrHPV) is now firmly established as
the cause of almost all cervical cancers, as well as a significant
proportion of other anogenital cancers and head and neck can-
cers in men and women (1). Both hrHPV and HIV are sexually
transmitted infectious agents and infection with either one of the
two viruses may facilitate transmission of the other (2, 3). Numer-
ous studies have shown that HIV-positive women have a higher
prevalence of hrHPV infections than HIV-negative women (4–6).
Moreover, hrHPV infections are more likely to be persistent in
HIV-positive women; and, a very high prevalence of high-grade
cervical cancer precursors referred to as cervical intraepithelial
neoplasia grades 2 and 3 (CIN 2 or 3) are found in HIV-positive
women (2–4, 6–8). Tumor registries and prospective follow-up
studies from the United States and Europe have shown the inci-
dence of invasive cervical cancer to be higher in HIV-positive
women (9–13).
The most important determinant of whether or not a hrHPV
infection will persist and progress to a CIN 2 or 3 lesion or an
invasive cervical cancer is the specific genotype of hrHPV with
which an individual is infected. For example, HPV 16 is associated
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with especially elevated rates of persistence and progression than
other hrHPV genotypes (14, 15). Some evidence suggests that
HIV-positive women are infected with a broader range of hrHPV
genotypes than HIV-negative women (16–18). If true, this would
have important implications for the effectiveness of both HPV
vaccination and the use of hrHPV genotyping assays for screen-
ing HIV-positive women. Relatively few large studies have directly
compared the distribution of hrHPV genotypes in HIV-positive
and -negative women of known cervical disease status; and, the
evaluation of HPV testing as a screening strategy among HIV-
positive women is warranted. Such studies are especially needed
for sub-Saharan African populations where the prevalence of both
HIV-infection and HPV-associated cervical cancer is particularly
high. There are approximately 23.5 million adults and children
living with HIV in sub-Saharan Africa; and, the incidence and mor-
tality from cervical cancer among women living in sub-Saharan
Africa are among the highest in the world with 70,000 new cases,
annually (19–21).
We have conducted several cervical cancer screening trials in
Cape Town, South Africa in which both HIV-positive and -negative
women were enrolled; and, disease endpoints were rigorously
ascertained using colposcopy and cervical biopsy. In a previous
study, we reported that HPV 16 and 35 were the most common
high-risk types among HIV-negative women (22); however, we
did not examine high-risk HPV genotypes among HIV-positive
women. In this study, we compare the distribution and preva-
lence of specific hrHPV genotypes in HIV-positive and -negative
women of known cervical disease status who were enrolled in
either one of three sequential cervical cancer screening studies
that we conducted in South Africa. We also compare the perfor-
mance of hrHPV testing as a screening test for cervical disease in
HIV-positive and -negative women.
MATERIALS AND METHODS
STUDY POPULATION
We report a secondary analysis of data collected as part of three
sequential studies that recruited healthy women from the general
population at three clinical sites in the community of Khayelit-
sha, Cape Town, South Africa. All three studies included women
who were not pregnant at the time of enrollment, had never been
screened or treated for cervical cancer, and had not undergone a
hysterectomy. Women were recruited through community out-
reach activities, including handing out fliers at bus and train
stations, meeting with church and women’s groups in the area,
and advertising on radio programs. All women provided written
informed consent; and, the protocols were approved by the Insti-
tutional Review Boards of Columbia University, New York, NY,
USA and the University of Cape Town, Cape Town, South Africa.
In Cohort 1, 191 HIV-positive and 2,505 HIV-negative women,
aged 35–65 years,were enrolled between January 1998 and Novem-
ber 1999 into a study evaluating the performance of different
tests for cervical cancer screening (23). In Cohort 2, 841 HIV-
positive and 5,708 HIV-negative women, aged 35–65 years, were
enrolled between June 2000 and December 2002 and were followed
for 36 months in a trial examining the safety and efficacy of two
screen-and-treat approaches for cervical cancer prevention (24).
For the analyses presented here, only women randomized to the
control group (284 HIV-positive and 1,881 HIV-negative) or to the
screen-and-treat arm utilizing HPV testing (286 HIV-positive and
1,874 HIV-negative) were included due to the availability of HPV
typing data, giving a total of 4,325 women in Cohort 2. In Cohort 3,
733 HIV-positive and 2,265 HIV-negative, aged 17–34 years, were
enrolled in a study between July 2004 and June 2006 examining
HPV prevalence among younger women. There were no duplicate
women in the three cohorts to our knowledge. For the current
analysis, we further restricted the study population by excluding
women with no known definitive cervical disease status (n= 574)
and women with invasive cervical cancer who were described sep-
arately in this study (n= 24), resulting in a final sample size of
1,371 HIV-positive and 8,050 HIV-negative women (190 HIV-
positive and 2,485 HIV-negative in Cohort 1, 494 HIV-positive
and 3,353 HIV-negative in Cohort 2, and 687 HIV-positive and
2,212 HIV-negative in Cohort 3).
STUDY PROCEDURES
In all three studies, a short risk factor questionnaire was con-
ducted at baseline and blood was collected for HIV testing. A
gynecologic examination was conducted in which cervical sam-
ples were obtained, including a sample collected from the exo-
and endo-cervix using a plastic spatula and cytobrush and placed
into liquid-based cytology (LBC) medium (ThinPrep PreservCyte,
Hologics, Marlborough, MA, USA), which was used for HPV test-
ing. Pap smears were evaluated at the University of Cape Town
Cytopathology Laboratory, Health Networks Laboratory, Allen-
town, PA, USA or Columbia University, New York, NY, USA and
were classified using the Bethesda System.
LABORATORY PROCEDURES
Hybrid capture 2 (HC2) DNA assay (Qiagen, Germantown, MD,
USA) was used to test cervical samples for HPV DNA types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (24). HPV DNA
positivity was based on a cut-off of relative light units (RLU) >1
time the positive control. All testing was done at the University of
Cape Town when the samples were collected. Aliquots of the LBC
samples were stored at−30°C and shipped to Columbia University
for future testing.
Stored cervical samples from all women who were HC2 posi-
tive were sought for determination of the specific HPV genotype
present. Of 9,421 women in the three cohorts, 2,389 samples tested
HPV positive by HC2 and 2,354 (98.5%) could be located and
further tested to determine the specific high-risk HPV genotype
present. DNA was isolated from 200µl of the LBC specimen (Qia-
gen, Chatsworth, CA, USA) and purified DNA was analyzed for
individual HPV genotypes using a prototype polymerase chain
reaction (PCR)-based line blot assay (kindly provided by Dr. Janet
Kornegay, Roche Molecular Diagnostics, Alameda, CA, USA) that
uses the PGMY09/11 consensus primers (25). If a high-risk HPV
genotype was not identified using the prototype line blot assay,
DNA was re-isolated and re-analyzed for individual HPV geno-
types using the PCR-based,Linear Array HPV Typing Assay (Roche
Molecular Diagnostics, Alameda, CA, USA) (25). HPV typing was
done in batches at Columbia University, Department of Pathology,
after the completion of each study following the manufacturers’
instructions and reagents provided at the time of each batch (25).
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DISEASE STATUS DETERMINATION
To meet the objectives of each study, slightly different protocols
were followed in each cohort to determine final disease status
[within normal limits (WNL), CIN (CIN) grade 1 (CIN 1), CIN
grade 2 (CIN 2), CIN grade 3 (CIN 3)]. In Cohort 1, all women
who had positive results on one or more of four independent
screening tests were referred for colposcopy 2–6 days after the
enrollment visit. The four screening tests were HPV DNA testing
using HC2, visual inspection with acetic acid, cytology (ASCUS
and above were referred), and expert cervicography (23). Approx-
imately half of the participants had one or more of the four
screening tests classified as positive and underwent colposcopy.
In Cohort 2, colposcopy was performed on all women at 6 and
12 months after enrollment (24). Samples for HPV DNA testing
were collected at the time of enrollment. In Cohort 3, all women
underwent colposcopy at their enrollment examination. Women
not found to have biopsy-confirmed CIN 2 or greater at the ini-
tial colposcopy who were HC2 positive, had cytology results of
≥ASCUS, or who had biopsy-confirmed CIN 1 lesions underwent
a second colposcopy 12 weeks after enrollment. Thus, for both
Cohorts 2 and 3, all subjects underwent at least one or more col-
poscopy examinations. Due to the fact that no cervical disease
was diagnosed in Cohort 2 or 3 among women who had both
negative HPV and cytology results, we can confirm that mini-
mal verification bias exists in Cohort 1. In all studies, colposcopy
was conducted by clinicians specifically trained in colposcopy
and according to a standard protocol. All abnormal areas were
biopsied and endocervical curettage specimens were collected.
Biopsy and endocervical curettage specimens were evaluated by
two pathologists at Columbia University. Inconsistent diagnoses
were adjudicated in a microscopic conference; and, the final dis-
ease status was based on the highest grade adjudicated pathology
diagnosis.
DATA ANALYSIS
Proportions were calculated and compared using Pearson’s chi-
square test or Fisher’s exact test where numbers were small.
Mann–Whitney U test was used to examine whether there were
differences in median values for continuous variables between
HIV status groups. HPV prevalence (HC2 DNA positivity) was
calculated as the number of positive women divided by the total
number of women. The distribution of HPV genotypes was calcu-
lated as the number of women with a specific high-risk HPV type
divided by the number of detected high-risk HPV types/infections
found among these women and also by dividing by the number
of women with any high-risk type. Analysis was conducted using
SAS statistical software (Cary, NC, USA).
RESULTS
STUDY POPULATION
Of the 9,421 women included, 14.6% (n= 1,371) were HIV-
positive. The prevalence of HIV increased from 20.1% in women,
aged 17–19 years, to a peak of 26.9% in women, aged 25–29 years,
and declined thereafter to 4.4% in women, aged 55–65 years
(Figure 1A). HIV-positive women were quite distinct from HIV-
negative women in demographic, HPV, and CIN parameters
(Table 1). HIV-positive women were younger, less educated, less
likely to be employed, and less likely to be married than HIV-
negative women (p< 0.0001). HIV-positive women had an earlier
age of first sexual intercourse and were more likely to be treated for
a sexually transmitted disease, but were more likely to use condoms
than HIV-negative women (p< 0.0001).
HIGH-RISK HPV PREVALENCE
The prevalence of high-risk HPV DNA detected by HC2 was
higher among HIV-positive than HIV-negative women within all
age groups. In the youngest age group (17–19 years), this difference
was the least marked: 75% of HIV-positive women were HPV DNA
positive compared to 60.2% of HIV-negative women (p= 0.06).
In older age groups, the prevalence of HPV DNA in HIV-positive
women was consistently more than twice that observed in HIV-
negative women. For example, the HPV prevalence in HIV-positive
vs. -negative women, aged 25–29 years and 35–39 years, was 59.7%
vs. 23.9% (p< 0.0001) and 46.4% vs. 19.3% (p< 0.0001), respec-
tively. For both HIV-positive and -negative women, the prevalence
of HPV declined steadily from the 17- to 19-year age category to
its lowest level among women in their 40’s (Figure 1B). In HIV-
positive women, there was a slight upward trend among women,
aged 50–54 years; however, there were only 28 women in this
group.
CERVICAL INTRAEPITHELIAL NEOPLASIA GRADES 2 AND 3
The prevalence of CIN 2 and CIN 3 was significantly higher among
HIV-positive women. The prevalence of CIN 2 was 7.2% among
HIV-positive vs. 1.6% among HIV-negative women (p< 0.001);
and, the prevalence of CIN 3 was 2.0% among HIV-positive vs.
1.1% among HIV-negative women (p< 0.001) (Table 1). As seen
in Figure 1C, this higher prevalence of CIN 2 or 3 in HIV-positive
vs. HIV-negative women was consistent across all age categories.
The differences in CIN 2 or 3 prevalence by HIV status were par-
ticularly marked among younger women (<35 years of age) but
remained statistically significant in the 35- to 39-year and 45- to
49-year age categories.
Restricting to those women who were HPV DNA positive,
the prevalence of CIN 1 and CIN 2, respectively, were higher
among HIV-positive (27.2% and 13.8%) than among HIV-
negative (12.0% and 6.5%) women. However, in those who were
HPV DNA positive, the prevalence of CIN 3 was not significantly
different by HIV status: 3.8% HIV-positive vs. 4.8% HIV-negative
women (Table 1).
PERFORMANCE CHARACTERISTICS OF HPV DNA TESTING
HIV status did not compromise the sensitivity of HPV testing to
detect any of the grades of disease. Rather, there was a greater sen-
sitivity of HPV testing to detect CIN among HIV-positive women,
although the sensitivity was high (>80%) in HIV-negative women
as well (Table 2). Specificity of HPV DNA testing was significantly
lower among HIV-positive compared to HIV-negative women.
Specificity was especially poor for HIV-positive women if CIN 1
was considered to be absence of disease. Inclusion or exclusion of
CIN 1 did not influence the specificity estimates as much for the
HIV-negative women. Positive predictive value was consistently
higher for HIV-positive than HIV-negative women except for the
detection of CIN 3, as mentioned above. Negative predictive value
was very high in both groups.
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A HIV prevalence by age
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
17-19
years
(n=239)
20-24
years
(n=914)
25-29
years
(n=905)
30-34
years
(n=841)
35-39
years
(n=2679)
40-44
years
(n=1547)
45-49
years
(n=1058)
50-54
years
(n=645)
55-65
years
(n=593)
HI
V
Pr
ev
al
en
ce
All Women
(N=9421)
B HPV prevalence by age
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
17-19
years
20-24
years
25-29
years
30-34
years
35-39
years
40-44
years
45-49
years
50-54
years
55-65
years
HP
V
Pr
ev
al
en
ce
HIV+ (N=1371)
HIV- (N=8050)
C CIN2/CIN 3 prevalence by age
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
17-19
years
20-24
years
25-29
years
30-34
years
35-39
years
40-44
years
45-49
years
50-54
years
55-65
years
CI
N
2 /
CI
N
3P
re
va
le
nc
e
HIV+ (N=1371)
HIV- (N=8050)
FIGURE 1 | Age-specific HIV, HPV, and cervical disease prevalence in 9,421 women recruited in CapeTown, South Africa. (A) HIV prevalence by age.
(B) HPV prevalence by age. (C) CIN2/CIN 3 prevalence by age. Note: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus. See Supplementary
Material for data.
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Table 1 | Characteristics of HIV-positive and HIV-negative women who participated in cervical cancer screening studies in Khayelitsha, South
Africa.
Overall (N =9,421) HIV-positive (N =1,371) HIV-negative (N =8,050) p-Value
Median age (25th and 75th percentile) 37 years (31–44 years) 34 years (26–38 years) 38 years (33–45 years) <0.0001
% ≤10 years of education 80.5% (7,579/9,421) 75.7% (1,038/1,371) 81.3% (6,541/8,050) <0.0001
% Currently employed 30.6% (2,878/9,401) 26.2% (359/1,370) 31.4% (2,519/8,031) 0.0001
% Smoker 5.5% (521/9,417) 6.5% (89/1,370) 5.4% (432/8,047) 0.0914
% Married 44.0% (4,148/9,421) 26.9% (369/1,371) 46.9% (3,779/8,050) <0.0001
Median age of first sexual intercourse (n; range) 17 years (9,416; 6–39 years) 16 years (1,369; 7–30 years) 17 years (8,047; 6–39 years) <0.0001
% Ever treated for STD 9.1% (858/9,403) 14.6% (200/1,371) 8.2% (658/8,032) <0.0001
% Ever used condoms 27.2% (2,288/8,404) 40.6% (524/1,290) 24.8% (1,764/7,114) <0.0001
% Disease status
WNL 91.3% (8,601/9,421) 75.3% (1,032/1,371) 94.0% (7,569/8,050) <0.0001a
CIN 1 5.0% (473/9,421) 15.5% (212/1,371) 3.2% (261/8,050)
CIN 2 2.5% (231/9,421) 7.2% (99/1,371) 1.6% (132/8,050)
CIN 3 1.2% (116/9,421) 2.0% (28/1,371) 1.1% (88/8,050)
% HPV DNA positive (HPV prevalence) 25.4% (2,389/9,421) 52.4% (719/1,371) 20.7% (1,670/8,050) <0.0001
% Disease status among HPV positives
WNL 70.3% (1,679/2,389) 55.2% (397/719) 76.8% (1,282/1,670) –
CIN 1 16.6% (396/2,389) 27.2% (196/719) 12.0% (200/1,670) <0.0001b
CIN 2 8.7% (207/2,389) 13.8% (99/719) 6.5% (108/1,670) <0.0001b
CIN 3 4.5% (107/2,389) 3.8% (27/719) 4.8% (80/1,670) 0.7081b
STD, sexually transmitted disease; HPV, human papillomavirus;WNL, within normal limits; CIN, cervical intraepithelial neoplasia;
ap-value for trend;
bp-value of the comparison of cervical disease withWNL between HIV-positive and -negative women.
Table 2 | Performance characteristics of HPV DNA testing using HC2 to detect different grades of disease among 1,371 HIV-positive and 8,050
HIV-negative women.
HIV-positive women HIV-negative women p-Value
Sensitivity to detect CIN 3a 96.4% (27/28) 90.9% (80/88) 0.6852
Sensitivity to detect CIN 2a 100% (99/99) 81.8% (108/132) <0.0001
Sensitivity to detect CIN 1a 92.5% (196/212) 76.6% (200/261) <0.0001
Sensitivity to detect CIN 2 or 3a 99.2% (126/127) 85.5% (188/220) <0.0001
Sensitivity to detect CIN 1, 2, or 3a 95.0% (322/339) 80.7% (388/481) <0.0001
Specificity (WNL)b 61.5% (635/1,032) 83.1% (6,287/7,569) <0.0001
Specificity (WNL or CIN 1)c 52.3% (651/1,244) 81.1% (6,348/7,830) <0.0001
Positive predictive value (CIN 2 or 3)c 17.5% (126/719) 11.3% (188/1,670) <0.0001
Positive predictive value (CIN 1, 2, or 3)a 44.8% (322/719) 23.2% (388/1,670) <0.0001
Negative predictive value (WNL)b 97.4% (635/652) 98.5% (6,287/6,380) 0.0242
Negative predictive value (WNL or CIN 1)c 99.8% (651/652) 99.5% (6,348/6,380) 0.3619
HPV, human papillomavirus;WNL, within normal limits; CIN, cervical intraepithelial neoplasia;
ap-value of the comparison between cervical disease(s) andWNL;
bp-value of the comparison betweenWNL and CIN 1/2/3;
cp-value of the comparison betweenWNL/CIN 1 and CIN 2/3.
DISTRIBUTION OF SPECIFIC HIGH-RISK HPV GENOTYPES
Of 2,354 women who tested HC2 positive and whose sam-
ples could be located and tested to determine the spe-
cific high-risk HPV genotype present, one or more high-
risk HPV genotypes were detected in 1,848 women [609/712
(85.5%) HIV-positive vs. 1,239/1,642 (75.5%) HIV-negative
women]. This detection was higher among women who
had CIN: 1,217 [315/395 (79.8%) HIV-positive vs. 902/1,261
(71.5%) HIV-negative] women with WNL, 349 [177/193 (91.7%)
HIV-positive vs. 172/198 (86.9%) HIV-negative] women with
CIN 1, 183 [90/97 (92.8%) HIV-positive vs. 93/103 (90.3%)
HIV-negative] women with CIN 2, and 99 [27/27 (100%)
HIV-positive vs. 72/80 (90%) HIV-negative] women with
CIN 3.
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Table 3 | Distribution of specific high-risk HPV genotypes among 609 HIV-positive women and 1,239 HIV-negative women with a high-risk
genotype detected by PCR.
WNL CIN 1 CIN 2 CIN 3
HIV-
positive
HIV-
negative
HIV-
positive
HIV-
negative
HIV-
positive
HIV-
negative
HIV-
positive
HIV-
negative
# Of women 1,032 7,569 212 261 99 132 28 88
# Of HC2 positive women 397 1,282 196 200 99 108 27 80
# Of PCR, HC2 positive women 395 1,261 193 198 97 103 27 80
# Women with HR types 315 902 177 172 90 93 27 72
# Of HR infection types 471 1,164 311 247 155 126 54 100
N (%)*
Type 16 45 (14.3) 146 (16.2) 33 (18.6) 23 (13.4) 20 (22.2) 21 (22.6) 14 (51.9) 29 (40.3)
Type 18 46 (14.6) 85 (9.4)* 26 (14.7) 22 (12.8) 9 (10.0) 9 (9.7) 4 (14.8) 8 (11.1)
Type 31 24 (7.6) 72 (8.0) 16 (9.0) 17 (9.9) 14 (15.6) 8 (8.6) 2 (7.4) 9 (12.5)
Type 33 29 (9.2) 67 (7.4) 13 (7.3) 15 (8.7) 10 (11.1) 12 (12.9) 7 (25.9) 9 (12.5)
Type 35 54 (17.1) 151 (16.7) 33 (18.6) 41 (23.8) 23 (25.6) 29 (31.2) 7 (25.9) 14 (19.4)
Type 39 25 (7.9) 51 (5.7) 17 (9.6) 7 (4.1)* 5 (5.6) 1 (1.1) 4 (14.8) 2 (2.8)*
Type 45 46 (14.6) 106 (11.8) 23 (13.0) 19 (11.1) 7 (7.8) 7 (7.5) 2 (7.4) 12 (16.7)
Type 51 29 (9.2) 75 (8.3) 30 (17.0) 23 (13.4) 11 (12.2) 5 (5.4) 0 (0) 1 (1.4)
Type 52 37 (11.8) 90 (10.0) 26 (14.7) 21 (12.2) 9 (10.0) 12 (12.9) 2 (7.4) 3 (4.2)
Type 56 22 (7.0) 56 (6.2) 19 (10.7) 15 (8.7) 8 (8.9) 3 (3.2) 2 (7.4) 1 (1.4)
Type 58 50 (15.9) 115 (12.8) 31 (17.5) 14 (8.1)* 22 (24.4) 13 (14.0) 5 (18.5) 9 (12.5)
Type 59 22 (7.0) 65 (7.2) 17 (9.6) 14 (8.1) 5 (5.6) 2 (2.2) 1 (3.7) 1 (1.4)
Type 68 42 (13.3) 85 (9.4) 27 (15.3) 16 (9.3) 12 (13.3) 4 (4.3)* 4 (14.8) 2 (2.8)*
Types 16/18 85 (27.0) 229 (25.4) 56 (31.6) 43 (25.0) 28 (31.1) 29 (31.28) 18 (66.7) 35 (48.6)
HPV, human papillomavirus; WNL, within normal limits; CIN, cervical intraepithelial neoplasia; HR, high-risk: *% is calculated using the number of women with any
high-risk HPV type as the denominator, *p-values <0.05.
Overall, the most common high-risk HPV genotypes among
both HIV-positive and HIV-negative women were HPV 16, 35,
and 58 (in descending order). There were only slight differences in
the high-risk HPV type distribution when the number of women
with high-risk HPV types was used as the denominator (Table 3).
Women with CIN 3 were more likely to have HPV 16 than women
with CIN 2 or less; this pattern was consistent across HIV-positive
and -negative women. The most common high-risk HPV types in
women with CIN 3 were the following: HPV 16, 33 and 35 (tied),
and 58 in HIV-positive women, and HPV 16, 35, and 45 in HIV-
negative women (in descending order). HIV-positive women had
more HPV 18 than HIV-negative women if they had no cervical
disease; they had more HPV 39 and 58 than HIV-negative women
if they had CIN 1; they had more HPV 68 than HIV-negative
women if they had CIN 2; and, they had more HPV 39 and HPV
68 than HIV-negative women if they had CIN 3 (p< 0.05 for each)
(Table 3). When the number of high-risk HPV infections was used
as the denominator (instead of the number of women with high-
risk types), there were no differences in the distribution of hrHPV
types by HIV status.
Further stratification by age as well as CIN status revealed some
differences in the distribution of HPV types by HIV status even
when using the number of high-risk infections as the denom-
inator. Among women, aged 40–65 years, with WNL or CIN 1,
HIV-positive women had a significantly greater representation
of HPV 18 and a significantly lesser representation of HPV 58
than HIV-negative women of similar age and cervical disease
status. Among women, aged 30–39 years, with WNL or CIN 1,
HIV-positive women had a significantly greater representation of
HPV 68 than HIV-negative women of similar age and cervical dis-
ease status (Figure 2). Among women, aged 17–29 years, with CIN
2 or 3, HIV-positive women had a significantly greater represen-
tation of HPV 56 and a significantly lesser representation of HPV
18 than HIV-negative women (Figure 3).
MULTIPLE HPV GENOTYPES
Table 4 shows the frequency of multiple HPV genotypes by age,
cervical disease, and HIV status among women with at least one
high-risk HPV genotype detected. In women with WNL or CIN
1, HIV-positive women had significantly more HPV infections
with multiple high-risk types than HIV-negative women across
all age groups. In women with CIN 2 or 3, the differences by
HIV status were weaker than the differences observed in women
with WNL or CIN 1. HIV-positive women with CIN 2 or 3 had
more multiple high-risk HPV types compared to HIV-negative
women; however, only HIV-positive women, aged 30–39 years, had
significantly more multiple high-risk HPV types than their HIV-
negative counterparts. The youngest age group, 17–29 years, had
more HPV infection with multiple high-risk types compared to
older age groups, regardless of cervical disease and HIV status.
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CERVICAL CANCER
Twenty-four women with cancer were identified (1 HIV-positive
woman and 23 HIV-negative women). The one HIV-positive
woman was HC2 negative and had no hrHPV types identified
on PCR. Among 23 HIV-negative women with cervical cancer, 19
(82.6%) were HC2 positive and 18 of these had a hrHPV type
detected by PCR. Fourteen of 18 (77.8%) had either HPV 16
(n= 10) or HPV 18 (n= 4); two (11.1%) women had HPV 45;
two (11.1%) women had HPV 58; and, one (5.6%) woman had
HPV 68.
HIV-posive women HIV-negave women
Type 16
9.5%
Type 18
7.9%
Type 31
5.3%
Type 33
5.8%
Type 35
9.7%
Type 39
6.6%Type 45
6.6%
Type 51
7.9%
Type 52
6.1%
Type 56
5.5%
Type 58
12.4%
Type 59
7.4%
Type 68
9.5%
WNL/CIN 1 (17-29 years)
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HPV 16 or 18 = 17%
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8.0%
Type 31
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Type 33
7.2%
Type 35
13.3%
Type 39
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Type 45
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Type 51
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Type 52
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Type 56
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Type 58
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Type 59
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Type 68
9.2%
WNL/CIN1 (17-29 years)
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Type 18
9.2%
Type 31
5.3%
Type 33
3.5%
Type 35
12.0%
Type 39
4.2%
Type 45
9.9%
Type 51
7.1%
Type 52
9.5%
Type 56
6.4%
Type 58
10.6%
Type 59
2.8% Type 68
9.2%
WNL/CIN 1 (30-39 years)
283 Infecons
HPV 16 or 18 = 18%
Type 16
12.1%
Type 18
7.6%
Type 31
7.4%
Type 33
5.2%
Type 35
13.7%
Type 39
3.6%
Type 45
11.2%
Type 51
6.1%
Type 52
9.7%
Type 56
4.5%
Type 58
8.8%
Type 59
4.9%
Type 68
5.2%
WNL/CIN1 (30-39 years)
445 Infecons
HPV 16 or 18 = 19%
Type 16
10.9%
Type 18
13.4%
Type 31
4.2%
Type 33
8.4%
Type 35
13.4%
Type 39
4.2%
Type 45
13.4%
Type 51
7.6%
Type 52
10.9%
Type 56
1.7%
Type 58
3.4%
Type 59
2.5%
Type 68
5.9%
WNL/CIN 1 (40-65 years)
119 Infecons
HPV 16 or 18 = 23%
Type 16
15.9%
Type 18
6.8%
Type 31
6.8%
Type 33
4.4%
Type 35
14.0%
Type 39
2.5%
Type 45
8.5%
Type 51
6.6%
Type 52
8.8%
Type 56
4.4%
Type 58
10.1%
Type 59
4.9% Type 68
6.3%
WNL/CIN1 (40-65 years)
365 Infecons
HPV 16 or 18 = 23%
FIGURE 2 | Age-specific distribution of high-risk HPV genotypes of 782
infections among 492 HIV-positive women and 1,411 infections among
1,074 HIV-negative women with within normal limits or cervical
intraepithelial neoplasia grade 1 only. Note: WNL, within normal limits;
CIN, cervical intraepithelial neoplasia; HR, high-risk; HPV, human
papillomavirus. See Supplementary Material for data.
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FIGURE 3 | Age-specific distribution of high-risk HPV genotypes of 209 infections among 117 HIV-positive women and 226 infections among 165
HIV-negative women with cervical intraepithelial neoplasia grade 2 or 3. Note: WNL, within normal limits; CIN, cervical intraepithelial neoplasia; HR,
high-risk; HPV, human papillomavirus. See Supplementary Material for data.
DISCUSSION
To our knowledge, our study is the largest one to date to compare
the distribution and prevalence of specific hrHPV genotypes in
sub-Saharan African HIV-positive and -negative women of known
cervical disease status. Our study confirms a higher overall preva-
lence of hrHPV infection, more cervical disease, and a greater
proportion of infections with multiple genotypes of hrHPV in
HIV-positive women compared to HIV-negative women. These
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Table 4 | Multiple high-risk types in HIV-positive (N =609) and -negative (N =1,239) women by age and disease status.
HIV-positive HIV-negative p-Value
(HIV+ vs. HIV−)
N with at least 1
HR type
Median
(range)
N with 1 HR
type (%)
N with 2+
types (%)
N with at least 1
HR type
Median
(range)
N with 1
HR type (%)
N with 2+
types (%)
WNL/CIN 1
17–29 years 221 1 (1–5) 120 (54.3) 101 (45.7) 403 1 (1–6) 264 (65.5) 139 (34.5) 0.0059
30–39 years 184 1 (1–7) 120 (65.2) 64 (34.8) 358 1 (1–4) 288 (80.5) 70 (19.6) <0.0001
40–65 years 87 1 (1–4) 64 (73.6) 23 (26.4) 313 1 (1–3) 264 (84.4) 49 (15.7) 0.0206
CIN 2/CIN 3
17–29 years 46 2 (1–4) 20 (43.5) 26 (56.5) 32 1 (1–6) 17 (53.1) 15 (46.9) 0.4013
30–39 years 56 2 (1–4) 26 (46.4) 30 (53.6) 62 1 (1–3) 49 (79.0) 13 (21.0) 0.0002
40–65 years 15 1 (1–3) 10 (66.7) 5 (33.3) 71 1 (1–4) 56 (78.9) 15 (21.1) 0.3093
Total population 609 1 (1–7) 360 (59.1) 249 (40.9) 1,239 1 (1–6) 938 (75.7) 301 (24.3) <0.0001
WNL, within normal limits; CIN, cervical intraepithelial neoplasia; HR, high-risk; N, number.
findings, although limited by the lack of detailed information on
the severity of HIV disease, are consistent with previous studies
reporting higher HPV prevalence (26–30), more cervical abnor-
malities (26, 29, 31), and more multiple high-risk HPV infections
(6, 8, 27–30, 32–34) in HIV-positive compared to HIV-negative
women. As shown in a large meta-analysis of hrHPV prevalence
studies in developing countries (35), the prevalence of hrHPV
infection in both groups of women was highest in young women
and steadily declined until age of 45–49 years, increasing some-
what in women, aged 50–54 years. Across almost all age groups,
the hrHPV prevalence in HIV-positive women was more than
twice that observed in HIV-negative women. Whether the higher
age-stratified prevalences among HIV-positive women are due
to greater HPV persistence/reactivation, behavior differences, or
consequences of HIV infection and concomitant immunosup-
pression, these factors can not be resolved with our data (36–38).
Nevertheless, the high HPV prevalences translate into high rates of
cervical precursor lesions, making HIV-positive women a priority
for public health interventions.
Only minor differences were observed in the relative distrib-
ution of hrHPV genotypes in HIV-positive women compared to
HIV-negative women when stratified by biopsy-confirmed cervi-
cal disease status. Since the histological diagnosis of CIN 1 is poorly
reproducible, we combined no cervical disease together with CIN
1 into a single category (39). Among the 593 HIV-positive and
1,482 HIV-negative women who were hrHPV-positive and had no
cervical disease or biopsy-confirmed CIN 1, not a single hrHPV
genotype had a significantly different prevalence based on HIV
serostatus. The most common hrHPV genotype was HPV 35,
closely followed by HPV 16 and 58. Because the hrHPV preva-
lence is so strongly affected by age, we also performed age-stratified
analyses. Although a few statistically significant differences by HIV
status were observed, the differences are likely explained by chance
and would not persist if adjustments were made for multiple
comparisons. Importantly for HPV vaccine effectiveness, the com-
bined prevalence of HPV 16 and 18 was almost identical between
HIV-positive and -negative women in all age groups. Similarly,
among women with biopsy-confirmed CIN 2 or CIN 3, not a sin-
gle hrHPV genotype had a significantly different prevalence by
HIV status. The most common hrHPV genotype in women with
biopsy-confirmed CIN 2 or CIN 3 was HPV 16, irrespective of
either HIV status or age. These results differ slightly from a meta-
analysis, which found less HPV 16 in HIV-positive women with
cytological high-grade squamous intraepithelial lesions (HSIL)
than in the general female population with HSIL (6). Data from
sub-Saharan Africa are more limited.
Interestingly and consistent with what has been reported, HPV
16 and 18 contributed to a larger proportion of high-risk HPV
types among women with CIN 3 (54%) than among women with
CIN 2 (31%). The relative proportion of high-risk HPV infections
attributable to HPV 16 and 18 was even greater still in women with
cancer (78%). We had only one HIV-positive woman with cancer
and therefore can not comment on likely differences in HPV geno-
type distribution by HIV status among women with cancer in this
population. One study of invasive cervical cancers from Kenya and
South Africa found a modest increase in HPV 18 among cancers
from HIV-positive women, but no significant differences for other
hrHPV genotypes (40).
As previously found, both CIN 2 and CIN 3 were much more
common in HIV-positive compared to HIV-negative women with
a combined prevalence of 9.2% vs. 2.7% in HIV-positive and
-negative women, respectively. This increase was observed in all
age groups. There remains controversy as to whether or not HIV
is associated with an increase in the incidence of cervical cancer
(9, 10, 13, 26). Therefore, it is of interest that when we restricted
comparisons to hrHPV-positive women; no difference was seen
in the prevalence of CIN 3 by HIV status. This finding is consis-
tent with what has been observed in some but not all studies from
the U.S. (4, 41, 42). These observations suggest that the impact
of HIV-infection on HPV-associated cancers is to increase sus-
ceptibility to infection with hrHPV or reactivation of previously
acquired hrHPV infection, but that HIV-infection does not neces-
sarily also influence progression rates to CIN 3 or invasive cervical
cancer. It is now well-recognized that, although persistent hrHPV
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infections are a prerequisite for development of CIN 3 and cervical
cancer, the pathogenesis of these lesions requires subsequent accu-
mulation of (epi)genetic alterations in the cells that allows them
to become immortalized and less sensitive to growth-modulating
factors (43).
The performance of cervical cancer screening tests including
hrHPV testing in HIV-positive and -negative women has been
previously studied (24, 44, 45). The current analysis confirms that
sensitivity of hrHPV testing as a screening test is not reduced
in HIV-positive women; but, the specificity is decreased. Guide-
lines from the U.S. currently do not recommend hrHPV testing
as screening for HIV-positive women given its low specificity even
though health economic models demonstrate that it is an appro-
priate screening approach (46, 47). Our finding that hrHPV testing
maintains a high sensitivity in HIV-positive women supports
using HPV testing as a primary screening test even in populations
with high HIV prevalence. Nevertheless, there remains a critical
research gap to develop additional triage tests, e.g., cancer bio-
markers such as p16 immunostaining or Ki67, to identify which
hrHPV-positive, HIV-positive women require additional work-up
and/or treatment.
A key strength of this study is the rigorous ascertainment of dis-
ease. All the colposcopy examinations were carried out by the same
team of highly experienced clinicians; and, all cervical biopsies
were reviewed by the same experienced gynecological pathologists,
providing consistency in the results. An important limitation is the
lack of clinical information about HIV disease status, such as HIV
viral load, CD4 cell counts, or use of antiretroviral therapy. Because
women were recruited from the general community, it is likely that
there is an under-representation of women with advanced HIV
disease. This may explain the lower hrHPV prevalence and biopsy-
confirmed CIN 2 and 3 rates we observed compared to other
studies enrolling at HIV care sites. Another limitation was that
the HC2 assay did not detect high-risk HPV types in some HC2
positive women. This was most marked in women without disease
and some may be explained by false-positive HC2 tests. Genotyp-
ing’s sensitivity improved in women with more advanced cervical
disease and was slightly better in HIV-positive vs. HIV-negative
women.
In conclusion, we have confirmed a high burden of hrHPV
infection including multiple type infections and biopsy-confirmed
CIN 2 or 3 in HIV-positive women in sub-Saharan Africa. HPV 16
and 35 were consistently the most common high-risk types among
HIV-positive and -negative women with or without cervical dis-
ease with little differences in the distribution of hrHPV genotypes
after stratifying by age and cervical disease status. These findings
suggest that screening strategies incorporating hrHPV genotyping
and vaccination should be effective in preventing cervical cancer in
HIV-positive and -negative women living in sub-Saharan Africa.
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